| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 23 | 2023 | 371 | 3.310 |
Why?
|
| Glioblastoma | 14 | 2023 | 219 | 2.050 |
Why?
|
| Glioma | 10 | 2022 | 140 | 1.690 |
Why?
|
| Spinal Cord Neoplasms | 3 | 2019 | 24 | 1.130 |
Why?
|
| Nervous System Diseases | 5 | 2022 | 142 | 1.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2006 | 36 | 0.980 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 468 | 0.940 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 446 | 0.910 |
Why?
|
| Bevacizumab | 2 | 2020 | 34 | 0.720 |
Why?
|
| Spinal Cord Diseases | 1 | 2019 | 23 | 0.660 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 66 | 0.650 |
Why?
|
| Thalidomide | 4 | 2014 | 24 | 0.560 |
Why?
|
| Sulfonamides | 4 | 2014 | 141 | 0.550 |
Why?
|
| Meningeal Neoplasms | 2 | 2005 | 42 | 0.470 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2004 | 73 | 0.440 |
Why?
|
| Spinal Cord Compression | 2 | 2011 | 23 | 0.440 |
Why?
|
| Humans | 52 | 2023 | 68618 | 0.390 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2019 | 77 | 0.390 |
Why?
|
| Radiotherapy | 4 | 2010 | 86 | 0.340 |
Why?
|
| Radiation Injuries | 2 | 2015 | 97 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 163 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2021 | 2223 | 0.310 |
Why?
|
| Allyl Compounds | 3 | 2018 | 29 | 0.290 |
Why?
|
| Sulfides | 3 | 2018 | 43 | 0.290 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 334 | 0.280 |
Why?
|
| Male | 25 | 2022 | 37321 | 0.280 |
Why?
|
| Syncope | 1 | 2005 | 23 | 0.260 |
Why?
|
| Aged | 12 | 2022 | 14862 | 0.260 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2018 | 116 | 0.260 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1070 | 0.260 |
Why?
|
| Head | 1 | 2005 | 59 | 0.250 |
Why?
|
| Parasomnias | 1 | 2005 | 2 | 0.250 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2005 | 29 | 0.250 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 99 | 0.250 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 40 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2022 | 57 | 0.250 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2004 | 4 | 0.250 |
Why?
|
| Middle Aged | 17 | 2022 | 21147 | 0.240 |
Why?
|
| Restless Legs Syndrome | 1 | 2004 | 18 | 0.240 |
Why?
|
| Adult | 17 | 2022 | 21403 | 0.230 |
Why?
|
| Pyrazoles | 4 | 2014 | 190 | 0.230 |
Why?
|
| Narcolepsy | 1 | 2004 | 45 | 0.230 |
Why?
|
| Meningitis | 1 | 2003 | 23 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 331 | 0.230 |
Why?
|
| Dacarbazine | 3 | 2014 | 32 | 0.220 |
Why?
|
| Deoxycytidine | 1 | 2003 | 83 | 0.220 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2003 | 11 | 0.220 |
Why?
|
| Drug Eruptions | 1 | 2003 | 16 | 0.220 |
Why?
|
| Isoenzymes | 1 | 2004 | 308 | 0.210 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 150 | 0.210 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 508 | 0.210 |
Why?
|
| Treatment Outcome | 5 | 2022 | 7029 | 0.210 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 5 | 0.210 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 475 | 0.200 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2002 | 6 | 0.200 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2021 | 25 | 0.200 |
Why?
|
| Dendritic Cells | 2 | 2023 | 201 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2022 | 66 | 0.190 |
Why?
|
| Diagnosis, Differential | 5 | 2021 | 1140 | 0.190 |
Why?
|
| Immunotherapy | 2 | 2022 | 215 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 36 | 0.190 |
Why?
|
| Catheters | 1 | 2021 | 39 | 0.190 |
Why?
|
| Oligodendroglioma | 1 | 2020 | 18 | 0.190 |
Why?
|
| Carboplatin | 1 | 2020 | 59 | 0.190 |
Why?
|
| Mutation | 2 | 2021 | 1213 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 170 | 0.180 |
Why?
|
| Female | 17 | 2022 | 38074 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 144 | 0.180 |
Why?
|
| Diagnostic Errors | 1 | 2020 | 100 | 0.180 |
Why?
|
| Necrosis | 2 | 2015 | 239 | 0.180 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 239 | 0.180 |
Why?
|
| Electrodiagnosis | 1 | 2019 | 12 | 0.170 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2019 | 12 | 0.170 |
Why?
|
| Injections, Spinal | 1 | 2019 | 18 | 0.170 |
Why?
|
| Biological Therapy | 1 | 2019 | 8 | 0.170 |
Why?
|
| Celecoxib | 4 | 2014 | 22 | 0.170 |
Why?
|
| Cytarabine | 1 | 2019 | 44 | 0.170 |
Why?
|
| Brain | 5 | 2022 | 2176 | 0.170 |
Why?
|
| Methotrexate | 1 | 2019 | 91 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 70 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2023 | 3705 | 0.160 |
Why?
|
| Physicians | 1 | 2022 | 324 | 0.160 |
Why?
|
| Postoperative Care | 1 | 2019 | 163 | 0.160 |
Why?
|
| Neoplasms | 1 | 2010 | 1667 | 0.160 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 951 | 0.150 |
Why?
|
| Isotretinoin | 2 | 2014 | 8 | 0.150 |
Why?
|
| Meningeal Carcinomatosis | 2 | 2021 | 5 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 349 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 4848 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2018 | 275 | 0.140 |
Why?
|
| Apoptosis | 4 | 2018 | 1641 | 0.130 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.130 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2324 | 0.130 |
Why?
|
| Limonins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Catechols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Flavones | 1 | 2015 | 11 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 332 | 0.130 |
Why?
|
| Lanosterol | 1 | 2015 | 11 | 0.130 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Heptanoic Acids | 1 | 2015 | 28 | 0.120 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 41 | 0.120 |
Why?
|
| Prognosis | 3 | 2021 | 2093 | 0.120 |
Why?
|
| Triterpenes | 1 | 2015 | 40 | 0.120 |
Why?
|
| Meningioma | 1 | 2015 | 54 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 1536 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2021 | 7277 | 0.110 |
Why?
|
| Young Adult | 6 | 2020 | 5717 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 163 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 33 | 0.110 |
Why?
|
| Disease Progression | 3 | 2021 | 1038 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 100 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2011 | 164 | 0.100 |
Why?
|
| Immune System Diseases | 1 | 2011 | 12 | 0.100 |
Why?
|
| Neuropil | 1 | 2010 | 6 | 0.090 |
Why?
|
| Recurrence | 2 | 2023 | 948 | 0.090 |
Why?
|
| Laminectomy | 1 | 2011 | 13 | 0.090 |
Why?
|
| Ganglioglioma | 1 | 2010 | 11 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 304 | 0.090 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2010 | 5 | 0.090 |
Why?
|
| Supratentorial Neoplasms | 1 | 2010 | 4 | 0.090 |
Why?
|
| Cryptococcosis | 1 | 2010 | 28 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 567 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 85 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 234 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 536 | 0.080 |
Why?
|
| Adolescent | 8 | 2014 | 8912 | 0.080 |
Why?
|
| Insomnia, Fatal Familial | 1 | 2009 | 1 | 0.080 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 626 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 511 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2007 | 26 | 0.070 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2007 | 14 | 0.070 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2006 | 3 | 0.070 |
Why?
|
| Subarachnoid Space | 1 | 2006 | 7 | 0.070 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2006 | 5 | 0.070 |
Why?
|
| Spinal Nerve Roots | 1 | 2006 | 9 | 0.070 |
Why?
|
| Meninges | 1 | 2006 | 7 | 0.070 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2006 | 8 | 0.070 |
Why?
|
| Peripheral Nerves | 1 | 2006 | 22 | 0.070 |
Why?
|
| Nerve Compression Syndromes | 1 | 2006 | 16 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 33 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 1851 | 0.070 |
Why?
|
| Herpes Zoster | 1 | 2006 | 43 | 0.070 |
Why?
|
| Muscles | 1 | 2006 | 158 | 0.070 |
Why?
|
| Neurons | 2 | 2018 | 881 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2009 | 342 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2018 | 238 | 0.060 |
Why?
|
| Peripheral Nervous System | 1 | 2005 | 12 | 0.060 |
Why?
|
| Disease Management | 2 | 2021 | 248 | 0.060 |
Why?
|
| Lymphoma | 1 | 2005 | 116 | 0.060 |
Why?
|
| Capecitabine | 1 | 2003 | 11 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 46 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 73 | 0.060 |
Why?
|
| Hyperkinesis | 1 | 2003 | 8 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 306 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2005 | 244 | 0.060 |
Why?
|
| Autopsy | 1 | 2003 | 56 | 0.060 |
Why?
|
| Epilepsies, Partial | 1 | 2003 | 24 | 0.060 |
Why?
|
| Prodrugs | 1 | 2003 | 54 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 160 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2003 | 62 | 0.060 |
Why?
|
| Animals | 5 | 2018 | 20881 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2003 | 130 | 0.060 |
Why?
|
| Pain | 1 | 2006 | 472 | 0.050 |
Why?
|
| Fatigue | 1 | 2004 | 132 | 0.050 |
Why?
|
| Palliative Care | 1 | 2005 | 271 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 800 | 0.050 |
Why?
|
| Chorea | 1 | 2002 | 4 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2003 | 411 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2022 | 6 | 0.050 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2002 | 15 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 129 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2022 | 31 | 0.050 |
Why?
|
| Survival Rate | 1 | 2005 | 1056 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2022 | 8 | 0.050 |
Why?
|
| Sleep | 1 | 2004 | 263 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2002 | 53 | 0.050 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 2002 | 3 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2022 | 26 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2003 | 141 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 40 | 0.050 |
Why?
|
| Carcinoma | 1 | 2003 | 215 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2004 | 142 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 31 | 0.050 |
Why?
|
| Retreatment | 1 | 2021 | 59 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 33 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2022 | 114 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 87 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 137 | 0.050 |
Why?
|
| Vaccination | 1 | 2023 | 189 | 0.050 |
Why?
|
| Convection | 1 | 2020 | 4 | 0.050 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 25 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 41 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2022 | 178 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 11 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2003 | 418 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2020 | 28 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 41 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 111 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 179 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2020 | 95 | 0.050 |
Why?
|
| Alleles | 1 | 2021 | 386 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2005 | 711 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 617 | 0.040 |
Why?
|
| Neurosurgical Procedures | 2 | 2010 | 98 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 786 | 0.040 |
Why?
|
| Incidence | 1 | 2003 | 1603 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 714 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 307 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 597 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 786 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 848 | 0.040 |
Why?
|
| Astrocytes | 1 | 2018 | 270 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 3259 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 57 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2015 | 85 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 64 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 2689 | 0.030 |
Why?
|
| Risk Factors | 1 | 2005 | 5731 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 57 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2015 | 152 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1753 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Benzamides | 1 | 2015 | 156 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 304 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1173 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 160 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 100 | 0.030 |
Why?
|
| Garlic | 1 | 2012 | 12 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2012 | 24 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2012 | 53 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 71 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 64 | 0.020 |
Why?
|
| Flavonoids | 1 | 2012 | 109 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1174 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 174 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 84 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 120 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 127 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 331 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 2083 | 0.020 |
Why?
|
| Retinoids | 1 | 2012 | 122 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 194 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 434 | 0.020 |
Why?
|
| Myokymia | 1 | 2009 | 2 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 756 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 84 | 0.020 |
Why?
|
| Camptothecin | 1 | 2008 | 39 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1118 | 0.020 |
Why?
|
| Forecasting | 1 | 2009 | 277 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 5300 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 21 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 447 | 0.020 |
Why?
|
| Pedigree | 1 | 2007 | 159 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2009 | 419 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2550 | 0.020 |
Why?
|
| Child | 2 | 2007 | 6405 | 0.010 |
Why?
|
| Registries | 1 | 2007 | 733 | 0.010 |
Why?
|
| Electromyography | 1 | 2003 | 184 | 0.010 |
Why?
|
| Gait Apraxia | 1 | 2002 | 1 | 0.010 |
Why?
|
| Purkinje Cells | 1 | 2002 | 18 | 0.010 |
Why?
|
| Video Recording | 1 | 2003 | 145 | 0.010 |
Why?
|
| Vertigo | 1 | 2002 | 24 | 0.010 |
Why?
|
| Electron Transport Complex II | 1 | 2002 | 1 | 0.010 |
Why?
|
| Mitochondria, Muscle | 1 | 2002 | 12 | 0.010 |
Why?
|
| Succinate Dehydrogenase | 1 | 2002 | 13 | 0.010 |
Why?
|
| Cell Count | 1 | 2002 | 248 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 50 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 351 | 0.010 |
Why?
|
| Cerebellum | 1 | 2002 | 103 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 2002 | 117 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 8474 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2003 | 189 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2002 | 453 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 1851 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 3187 | 0.010 |
Why?
|